0001562180-23-001330.txt : 20230213
0001562180-23-001330.hdr.sgml : 20230213
20230213165653
ACCESSION NUMBER: 0001562180-23-001330
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230209
FILED AS OF DATE: 20230213
DATE AS OF CHANGE: 20230213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lurker Nancy
CENTRAL INDEX KEY: 0001450485
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51122
FILM NUMBER: 23619502
MAIL ADDRESS:
STREET 1: PDI, INC.
STREET 2: 1 ROUTE 17 SOUTH
CITY: SADDLE RIVER
STATE: NJ
ZIP: 07458
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001314102
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 262774444
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-926-5000
MAIL ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida Corp.
DATE OF NAME CHANGE: 20080619
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida LTD
DATE OF NAME CHANGE: 20050111
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2023-02-09
false
0001314102
EyePoint Pharmaceuticals, Inc.
EYPT
0001450485
Lurker Nancy
C/O EYEPOINT PHARMACEUTICALS, INC.
480 PLEASANT STREET
WATERTOWN
MA
02472
true
true
false
false
CEO
Common Stock
2023-02-09
4
M
false
17533.00
0.00
A
170559.00
D
Common Stock
2023-02-09
4
M
false
20000.00
0.00
A
190559.00
D
Restricted Stock Units
0.00
2023-02-09
4
M
false
20000.00
0.00
D
Common Stock
20000.00
40000.00
D
Restricted Stock Units
0.00
2023-02-09
4
M
false
17533.00
0.00
D
Common Stock
17533.00
17534.00
D
Includes 2,745 shares acquired on January 31, 2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
The restricted stock units vest in three annual installments beginning February 9, 2023.
The restricted stock units vest in three ratable annual installments beginning February 9, 2022.
/s/ Ron Honig, Attorney-in-Fact
2023-02-13